A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD

Yu Ri Im, Harriet Hunter, Dana de Gracia Hahn, Amedine Duret, Qinrong Cheah, Jiawen Dong, Madison Fairey, Clarissa Hjalmarsson, Alice Li, Hong Kai Lim, Lorcán McKeown, Claudia-Gabriela Mitrofan, Raunak Rao, Mrudula Utukuri, Ian A. Rowe, and Jake P. Mann

BACKGROUND AND AIMS: Animal models of human disease are a key component of translational hepatology research, yet there is no consensus on which model is optimal for NAFLD.

APPROACH AND RESULTS: We generated a database of 3,920 rodent models of NAFLD. Study designs were highly heterogeneous, and therefore, few models had been cited more than once. Analysis of genetic models supported the current evidence for the role of adipose dysfunction and suggested a role for innate immunity in the progression of NAFLD. We identified that high-fat, high-fructose diets most closely recapitulate the human phenotype of NAFLD. There was substantial variability in the nomenclature of animal models: a consensus on terminology of specialist diets is needed. More broadly, this analysis demonstrates the variability in preclinical study design, which has wider implications for the reproducibility of in vivo experiments both in the field of hepatology and beyond.

CONCLUSIONS: This systematic analysis provides a framework for phenotypic assessment of NAFLD models and highlights the need for increased standardization and replication.

NAFLD is a slowly progressive condition characterized by accumulation of excess hepatic lipids. Some individuals go on to develop NASH that drives fibrosis, which in turn can lead to cirrhosis and HCC. The burden and mortality associated with NAFLD are increasing rapidly, especially in developed countries.

NAFLD is causally associated with insulin resistance, typically through obesity. Individuals with the most severe insulin resistance and metabolic risk factors are at greatest risk of progressive liver disease, which has been reflected in the recently coined term “metabolic dysfunction–associated fatty liver disease.” On the other hand, some common genetic variants (e.g., p.Ile148Met in patatin-like phospholipase domain containing 3 [PNPLA3]) may lead to the development of NAFLD with lower levels of insulin resistance. Almost all such variants perturb hepatic lipid metabolism, and there has been little human genetic evidence for the inflammatory or fibrotic aspects of NASH.

Histologically, fatty liver disease manifests with a spectrum of histological features on liver biopsy in humans, including steatosis, lobular and periportal inflammation, hepatocellular ballooning, and fibrosis. Simple steatosis can be distinguished from NASH through assessment by pathologists as the latter typically requires the presence of lobular inflammation and hepatocellular ballooning.
Animal models of human diseases are an integral part of preclinical research, allowing researchers to facilitate mechanistic and therapeutic studies that are not possible in humans. Studies of NAFLD predominantly use rodent models of obesity (or insulin resistance) to induce hepatic steatosis. However, it remains unclear which rodent models most closely reflect the human disease phenotype.

The theoretical “ideal” NAFLD model should reflect the full human spectrum of hepatic disease clinically, biochemically, and histologically, plus features of the associated metabolic syndrome. It would pass through these stages without taking an unacceptably long duration (such as over 1 year).

We have recently found that variation in study design (e.g., percentage kilocalories from fat in diet, age of mice) has a significant effect on response to therapeutic pharmacological agents in rodent models of NAFLD. Therefore, detailed appraisal of preclinical study design is vitally important for reproducibility, particularly given that some recent high-profile studies could not be replicated in the field.

To address these questions, we systematically reviewed and categorized NAFLD models from over 4,500 published studies. We interrogated features of the human metabolic phenotype, histological features, and gene expression in the animal models to identify the rodent model(s) most resembling human NAFLD.

Materials and Methods

PROTOCOL AND SEARCH STRATEGY

The systematic review protocol was prospectively registered with the Systematic Review Facility in August 2017 and is available from https://drive.google.com/file/d/0B7Z0eAxKc8ApQ0p4OG5lbIRlRTA/view. A partial analysis of this data set has been reported elsewhere.

PubMed on MEDLINE, EMBASE, and the National Center for Biotechnology Information’s Gene Expression Omnibus were searched for published articles of experimental rodent models of fatty liver, NAFLD, or NASH. The search was completed in January 2019.

STUDY SELECTION AND ELIGIBILITY CRITERIA

Our inclusion criteria were primary research articles using mice or rats to model NAFLD (to include hepatic steatosis, NASH, and NASH-fibrosis) and evidence of hepatic steatosis in model rodents through either increased hepatic triglyceride content or histological assessment. Studies were excluded if they did not model NAFLD/NASH; they were in humans or any animal other than mice and rats; they were reviews, comments, letters, editorials, meta-analyses, or ideas; or they were not in English (unless there was an available translation).

Abstracts and titles were screened to identify relevant studies using Rayyan. Potentially relevant studies had their full text extracted and were assessed against inclusion/exclusion criteria independently by two reviewers, with discrepancies settled by discussion with J.P.M.

DATA COLLECTION

The variables extracted were as follows: phenotypic characteristics of animal model used (e.g., sex, dietary composition, rodent age, genetic alterations,
background animal strain, chemical agents, genetic manipulations), features of metabolic syndrome (obesity, dyslipidemia, insulin resistance), presence of lipodystrophy, features of NAFLD (elevated aminotransferases, lobular inflammation, hepatocellular ballooning, portal inflammation, NASH, fibrosis [stage, if stated], HCC), and age (in weeks). Where data had been deposited in the Gene Expression Omnibus, the accession number was extracted. Mouse Genome Informatics was used to find human orthologues for murine genes perturbed in genetically modified animals. (14)

The presence or absence of phenotypic characteristics was based on the reported description in the included article. Lipodystrophy was defined as the presence of reduced fat mass plus increased insulin resistance and where the animals were described as lipodystrophic. Obesity was defined as a significantly higher body weight (or fat mass) than control animals. Insulin resistance was defined as a significant elevation in any of the following: fasting or postprandial glucose or insulin, homeostatic model assessment of insulin resistance, greater AUC on glucose or insulin tolerance test, or lower glucose infusion rate during hyperinsulinemic–euglycemic clamp studies. Dyslipidemia was defined by any of the following: higher triglycerides, lower HDL, higher cholesterol, or higher LDL. Elevated aminotransferases were defined by significantly higher alanine or aspartate aminotransferase compared to control animals. Presence or absence of NASH was assessed dichotomously based on description in the article. Many models were dichotomously described to show the presence or absence of fibrosis without further details; therefore, this was collected in addition to fibrosis stage (where available), which was extracted according to Kleiner staging. (15)

Genetically modified animals were included as separate models where they were shown to exacerbate the liver phenotype of NAFLD. If a study reported a “negative control” animal, a model with NAFLD (“positive control”), and a genetically modified animal with less severe NAFLD than the “positive control,” the genetically modified animal would not be included as a separate model of NAFLD.

Studies frequently included multiple model designs (or treatment arms for interventional studies). Data were extracted for each model or interventional arm separately. Where data from male and female animals were reported separately, they were included as separate models. The complete raw data set has been deposited as a Dryad database (https://doi.org/10.5061/dryad.pnvx0k6kq).

COMPARISON OF MODELS FOR SIMILARITY

Models were compared for similarity based on study design. Criteria for considering two models to be the same were chosen manually given the recent finding that most outcomes in rodent models of NAFLD could be modeled in a continuous fashion (11) and included identical genetic background, sex of animals studied, age diet initiated ±1 week, kilocalories of diet from fat ±2%, weight of cholesterol in diet ±0.1%, weight of choline in diet ±0.1%, kilocalories of diet from sucrose ±2%, fructose–glucose in diet ±2% kcal (or ±2 g/L where dissolved in drinking water), age given chemical/virus/surgery ±1 week, dose of chemical ±10% (chemical–specific), and identical route of administration of chemical. Models could be combined using variables that were not reported (e.g., studies not reporting sex, but otherwise identical models, would be considered the same).

Models were organized into three levels: category, main group, and subgroup. This was based on the similarity of model design after data extraction, rather than on terminology used in the original article. For example, a model using 45% kcal fat plus 20% kcal fructose would be categorized as “diet only” > “high fat, high carbohydrate” > “high fat, high fructose,” even if the authors described the model as a “high-fat diet” (HFD). The article’s original description used for each model was retained for comparison of nomenclature with study design.

COMPARISON OF MODELS WITH HUMAN PHENOTYPE

A metabolic syndrome score (range 0-3) and a liver histology score (range 0-11) were used to assess the similarity of each model to human NAFLD (Supporting Table S1). For the metabolic syndrome score, models scored 1 for each of the following: obesity, insulin resistance, and dyslipidemia. For liver histology, models scored 1 for each of the following:
raised aminotransferases, lobular inflammation, portal inflammation, hepatocellular ballooning, NASH, fibrosis (presence/absence), fibrosis stages 1-4 (1 point for each), and HCC. The scoring of histological features was based upon the author’s reported presence or absence of each feature, with the definition of each histological characteristic according to that of the (human) NASH Clinical Research Network. Presence or absence of NASH was based on the author’s reported global histological assessment (i.e., no score cutoff was used). These two scores were combined to give an overall phenotype score (range 0-14). Scores were only recorded where suitable data were reported.

**RISK OF BIAS ASSESSMENT**

Each paper was assessed in the following four areas: reporting the presence of a protocol, reporting use of randomization, reporting use of blinding, and a power calculation for sample size estimation. These were each given a score of 1, and each paper was assigned an overall “risk of bias score.”

**STATISTICAL ANALYSIS**

For comparison of phenotype scores by subgroup, models were filtered for those that had been used by at least one study, and then subgroups were filtered for those that contained at least three models. Gene lists were analyzed using the EnrichR package for R. Histograms and descriptive statistics were extracted using R 3.6.2 for Mac. The code used in the analysis is available from https://doi.org/10.5281/zenodo.4656980.

**Results**

**THE LANDSCAPE OF ANIMAL MODELS OF NAFLD**

In order to understand the spectrum of animal models used to study fatty liver disease, we screened 8,727 published articles and included 4,540 articles in our final analysis (Fig. 1). From this, we built a database of 3,920 unique rodent models of NAFLD, which we grouped into nine broad categories of model (Table 1; Supporting Tables S2 and S3). These could be further subdivided into 29 main groups (e.g., “high-fat, high-cholesterol diet”) and 771 subgroups (e.g., “apolipoprotein E [ApoE] mutant with dietary manipulation”).

The most common category of model was dietary (1,927/3,920), followed by genetically altered rodents combined with dietary manipulation (826/3,920). The majority of models were conducted using only male animals (2,777/3,920, 82%); therefore, a direct comparison of female versus male animals was limited except for the three subgroups where sufficient data were available, and no consistent trend was observed (Supporting Fig. S1).

Of the models, 27% (1,055/3,920) were performed using C57BL/6J mice, with hundreds of other genetic backgrounds represented (Supporting Table S4). Twelve weeks was the modal duration of model study (mean = 15 weeks) (Fig. 2A). Study duration was similar for the assessment of all histological features except for the presence of HCC, which was reported at up to 2 years of age (Supporting Fig. S2). Where described, studies were almost uniformly performed at room temperature (20-22°C); and therefore, this was not included as a variable in subsequent analyses. A single study assessed the effect of housing at thermoneutrality (30°C) and found this to exacerbate the HFD phenotype, resulting in a phenotype that more closely mirrored human NASH.

**REPLICATION OF MODEL DESIGN**

Due to differences in model design (e.g., proportion of fat in diet, age diet initiated, genetic background), models were used by a mean of just 1.6 studies (median 1 study). Genetic models fed standard chow were used by a mean 2.2 studies, compared to only 1.1 for genetic models with dietary manipulation. There was a trend that more complex models (e.g., offspring, chemical plus dietary) were more likely to be used by a single study only. The most frequently used model was male leptin-deficient (ob/ob) mice on a pure C57BL/6J background fed standard chow (Table 2).

**COMPARABILITY OF MODELS TO HUMAN NAFLD**

In order to compare the rodent models to that of human NAFLD, we examined the metabolic
phenotype, histology, and gene expression in the animal models.

**METABOLIC PHENOTYPE**

Of the models, 44% were reported to show insulin resistance, 47% were obese, and 51% had dyslipidemia. Of the models, 47% (1,839/3,920) had at least two features of the metabolic syndrome (Fig. 2D). Chemically induced models were less frequently reported to show metabolic features of NAFLD (e.g., 26% with obesity).

**HISTOLOGY**

Of the models, 93% (3,655/3,920) reported liver histology. Overall, 35% of models were reported to show NASH and 23% to show some stage of fibrosis, whereas the presence or absence of periportal inflammation was described in only 9% of models (Supporting Fig. S1).

No model was reported to recapitulate all possible features of NAFLD liver histology and the metabolic syndrome. Three models had an overall NAFLD model score of 13 (out of 14). Only one of these three models had been used in at least two studies, i.e., replicated (Table 3). All models, their NAFLD phenotype scores, and studies using each model can be viewed in Supporting Tables S2 and S3. The three highest-scoring models were 10-week-old male C57BL/6J-129/SvlmJ mice fed a 42% calorie fat, 0.1% cholesterol diet and given 55% fructose of 42 g/L water *ad libitum* for 8 weeks, used by two studies (20,21); 7-week-old male C57BL/6?–129 mice fed a 45% calorie fat diet and given 55% fructose of 42 g/L water *ad libitum* for 24 weeks, used in only one study (22); and 9-week-old C57BL/6J mice fed a “Western diet” (fed a diet with 42% calories due to fat, 1.25% weight due to cholesterol, 37.3% calories due to sucrose, and given 55% fructose of 42 g/L water *ad libitum*) for 12-24 weeks, used by one study (23). Hence, two of the models were based on a high-fat, high-fructose
| Category                          | Overall | Dietary | Dietary + Other | Genetic | Genetic + Chemical | Genetic + Dietary | Genetic + Other | Chemical | Offspring | Other |
|----------------------------------|---------|---------|----------------|---------|-------------------|------------------|----------------|----------|-----------|-------|
| Number of models                 | 3,920   | 1,927   | 68             | 477     | 65                | 826              | 26            | 391      | 91        | 49    |
| Main groups                      | 29      | 14      | 9              | 8       | 7                 | 8                | 6             | 3        | 4         | 4     |
| Subgroups                        | 771     | 44      | 16             | 275     | 32                | 359              | 23            | 28       | 15        | 14    |
| Sex                              | 175 (5.2%) | 81 (4.7%) | 2 (3%) | 14 (4.3%) | 47 (6.7%) | 1 (4.8%) | 10 (2.7%) | 19 (2.2%) | 1 (2.3%) |
| Female                           | 444 (13.1%) | 180 (10.4%) | 32 (48.5%) | 47 (14.6%) | 7 (1.3%) | 78 (11.1%) | 5 (23.8%) | 52 (14.2%) | 26 (30.2%) | 17 (38.6%) |
| Male                             | 2,777 (81.8%) | 1,476 (85.0%) | 32 (48.5%) | 261 (81.1%) | 44 (18.6%) | 578 (82.2%) | 15 (71.4%) | 304 (83.1%) | 41 (47.7%) | 26 (59.1%) |
| Age diet started                 | 7.0 (0.1) | 7.0 (0.1) | 7.8 (0.3) | 8.0 (0.8) | 8.0 (0.2) | 8.0 (0.8) | 6.0 (0.2) | 4.0 (0.5) | 8.0 (0.6) |
| Fat in diet (%kcal)              | 45.0 (0.3) | 44.5 (0.4) | 45.0 (1.8) | 45.0 (0.5) | 42.5 (0.5) | 42.5 (0.8) | 42.5 (0.2) | 19.9 (0.2) | 34.7 (3.1) |
| Cholesterol in diet (%weight)    | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 0.3 (0.07) | 2.0 (0.07) | 2.0 (0.23) | 2.0 (0.23) |
| Sucrose in diet (%kcal)          | 29.0 (0.3) | 26.2 (0.4) | 32.0 (1.8) | 17.4 (1.5) | 17.4 (1.5) | 21.7 (2.4) | 17.4 (1.5) | 32.0 (1.8) | 37.5 (4.5) |
| Fructose in diet (%weight)       | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) | 1.0 (0.03) |
| Lipodystrophy                    | 48 (1.2%) | 48 (1.2%) | 48 (1.2%) | 33 (6.9%) | 33 (6.9%) | 44 (5.1%) | 44 (5.1%) | 44 (5.1%) | 44 (5.1%) |
| Metabolic syndrome features      | 1,855 (47.3%) | 1,011 (52.5%) | 41 (60.3%) | 154 (32.3%) | 40 (53.3%) | 10 (38.5%) | 100 (25.6%) | 47 (51.6%) | 21 (42.9%) |
| Insulin-resistant                | 1,709 (43.6%) | 846 (43.9%) | 24 (35.3%) | 212 (44.4%) | 212 (44.4%) | 80 (15.7%) | 80 (15.7%) | 12 (23.1%) | 12 (23.1%) |
| Dyslipidemia                     | 1,993 (50.8%) | 1,025 (53.2%) | 27 (39.7%) | 234 (49.1%) | 234 (49.1%) | 156 (30.7%) | 156 (30.7%) | 156 (30.7%) | 156 (30.7%) |
| Raised transaminases             | 1,663 (42.4%) | 880 (45.7%) | 30 (44.1%) | 139 (29.1%) | 139 (29.1%) | 100 (25.6%) | 100 (25.6%) | 100 (25.6%) | 100 (25.6%) |
| Lobular inflammation             | 772 (19.7%) | 408 (21.2%) | 16 (23.5%) | 58 (12.2%) | 58 (12.2%) | 26 (50.5%) | 26 (50.5%) | 26 (50.5%) | 26 (50.5%) |
| Hepatocellular ballooning        | 745 (19.0%) | 411 (21.3%) | 10 (14.7%) | 48 (10.1%) | 48 (10.1%) | 18 (30.5%) | 18 (30.5%) | 18 (30.5%) | 18 (30.5%) |
| Steatohepatitis                  | 1,369 (34.9%) | 718 (37.3%) | 19 (27.9%) | 100 (21.0%) | 100 (21.0%) | 26 (40.0%) | 26 (40.0%) | 26 (40.0%) | 26 (40.0%) |
| Peri-Portal inflammation        | 167 (4.3%) | 106 (5.5%) | 4 (5.9%) | 18 (3.8%) | 18 (3.8%) | 21 (5.2%) | 21 (5.2%) | 21 (5.2%) | 21 (5.2%) |
| Fibrosis                         | 891 (22.7%) | 455 (23.6%) | 17 (25.0%) | 75 (15.7%) | 75 (15.7%) | 21 (5.2%) | 21 (5.2%) | 21 (5.2%) | 21 (5.2%) |
| HCC                              | 177 (4.5%) | 34 (1.8%) | 4 (5.9%) | 50 (10.5%) | 50 (10.5%) | 19 (3.8%) | 19 (3.8%) | 19 (3.8%) | 19 (3.8%) |
| Citations per model              | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 |
| Range                            | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) | (1.0-9.0) |

Data from 4,540 studies reporting 3,920 unique NAFLD models, divided into nine categories.
and added cholesterol diet, and all three included a high-fat, high-fructose diet, suggesting that a high-fat, high-fructose diet yields a metabolic and histological phenotype that resembles human NAFLD.

This was supported on analysis of phenotype scores by subgroups (Fig. 2E). While choline-deficient diets had the highest mean liver histology scores, they had few features of the metabolic syndrome.

FIG. 2. Phenotype score and duration of rodent models of NAFLD. (A) Histogram illustrating the maximum duration each model (n = 3,920) was studied. (B) Overall phenotype score for each model (0–14) generated from a combination of liver histology score and metabolic syndrome score. (C) Liver histology score (0–11) for each model, where 1 point is given for the presence of each histological feature of human NAFLD, including fibrosis stages 1–4 and HCC, plus raised aminotransferases. (D) Metabolic syndrome score (0–3) for each model was calculated as the presence of obesity, insulin resistance, and dyslipidemia, with 1 point for each. (E) Comparison of mean (±SE) scores for subgroups of models with at least three models, which had all been replicated at least once. Abbreviations: CDAA, choline-deficient, amino acid–defined diet; MCD, methionine-/choline-deficient diet; STZ, streptozocin.
### TABLE 2. Most frequently used rodent NAFLD models

| Model Name | Background | Sex | Age Started (Weeks) | Fat (% kcal) | Cholesterol (% weight) | Diet | Chemical | Insulin Resistance | Metabolic Syndrome | Phenotype Score | ballooning | NASH | Fibrosis | HCC | Timing of Weeks | Number of Citations |
|------------|------------|-----|--------------------|-------------|------------------------|------|----------|-------------------|-------------------|----------------|------------|------|----------|-----|----------------|----------------------------|
| Leptin deficiency (ob/ob) | C57BL/6J | M | 8 | 60 | | HFD | | Yes | Yes | Yes | 3 | 7 | 10 | Yes | 10 | Yes | 48 | 2 | 21 | Life | 90 (e.g., PMID 24205128) |
| Zucker (fa/faith) | Zucker | | | | | | | Yes | Yes | Yes | 3 | 8 | 11 | Yes | 29 | Yes | 16 | 1 | 34 | Yes | 60 | Diet | 78 (e.g., PMID 23197411) |
| MCD | C57BL/6J | M | 8 | | | | | No | No | Yes | 1 | 8 | 9 | Yes | 18 | Yes | 18 | 3 | 18 | | | Diet | 43 (e.g., PMID 28190475) |
| HFD | C57BL/6J | M | 8 | | | | | No | ? | Yes | 1 | 7 | 8 | Yes | 18 | Yes | 20 | 2 | 20 | | | Diet | 36 (e.g., PMID 26979540) |
| Zucker (fa/faith) | Zucker | | | | | | | Yes | Yes | Yes | 3 | 4 | 7 | Yes | 28 | Yes | 28 | Yes | NR | 24 | | | Diet | 35 (e.g., PMID 26004704) |
| OLETF rat | Long-Evans | M | 5 | 60 | | HFD | | Yes | Yes | Yes | 3 | 7 | 10 | Yes | 24 | Yes | 26 | 1 | 24 | | | Diet | 34 (e.g., PMID 23774190) |
| Leptin deficiency (ob/ob) | C57BL/6J | M | 8 | | | | | Yes | Yes | Yes | 3 | 6 | 9 | ? | 40 | Yes | 40 | 1 | 40 | | | Life | 33 (e.g., PMID 11100100) |
| HFD | C57BL/6J | M | 8 | | | | | No | No | Yes | 3 | 2 | 5 | ? | 9 | No | 12 | Yes | NR | 20 | | | Life | 30 (e.g., PMID 27997977) |
| MCD | C57BL/6J | M | 8 | | | | | No | No | Yes | 3 | 2 | 5 | | | | | | | | | | | | |
| MCD | C57BL/6J | M | 8 | | | | | Yes | Yes | Yes | 3 | 4 | 7 | Yes | 12 | Yes | 22 | No | 18 | | | Diet | 26 (e.g., PMID 27004001) |
| Zucker (fa/faith) | Zucker | | | | | | | Yes | Yes | Yes | 3 | 4 | 7 | Yes | 12 | Yes | 22 | No | 18 | | | Diet | 26 (e.g., PMID 27004001) |
| HFD | C57BL/6J | M | 7 | 60 | | HFD | | Yes | Yes | Yes | 3 | 6 | 9 | Yes | 40 | Yes | 40 | 1 | 40 | | | Diet | 23 (e.g., PMID 28597936) |
| Zucker (fa/faith) | Zucker | | | | | | | Yes | Yes | Yes | 3 | 3 | 6 | Yes | 18 | Yes | 18 | No | 18 | | | Life | 18 (e.g., PMID 27997977) |
| LepR deficiency (db/db) | C57BL/6J | M | 8 | 45 | | HFD | | Yes | Yes | Yes | 3 | 4 | 7 | Yes | 20 | Yes | 20 | No | 52 | | | Life | 26 (e.g., PMID 25643501) |
| HFD | C57BL/6J | M | 6 | | | | | Yes | Yes | Yes | 3 | 4 | 7 | Yes | 12 | Yes | 22 | No | 18 | | | Diet | 26 (e.g., PMID 27004001) |
| HFD | C57BL/6J | M | 8 | | | | | Yes | Yes | Yes | 3 | 2 | 5 | No | 12 | Yes | 21 | No | 21 | | | Life | 24 (e.g., PMID 25420998) |
| Zucker (fa/faith) | Zucker | | | | | | | Yes | Yes | Yes | 3 | 1 | 4 | | | | | | | | | | | | |
| HFD + STZ | C57BL/6J | M | 4 | 57 | 0.29 | No | | Yes | Yes | Yes | 3 | 9 | 12 | Yes | 13 | Yes | 13 | 3 | 12 | Yes | 20 | | | Life | 12 (e.g., PMID 28512251) |
We also used our database of NAFLD models to identify rodent studies reporting the presence of cirrhosis in under 20 weeks (Supporting Table S5). The majority of these used choline-deficient diets, with or without methionine deficiency. Other models, including diet-induced obesity designs (e.g., 60% kcal HFD), were reported to cause advanced fibrosis (NAFLD fibrosis score > F3), but this was after a duration of 40-50 weeks.

Similarly, HCC developed in these obese rodents models typically after 1-2 years, which would require a protracted study period. Therefore, we searched our database to identify models showing HCC at under 30 weeks (Supporting Table S5). This again highlighted methionine-/-choline-/-deficient models, as well as chemically manipulated models, whereby rodents received diethylnitrosamine or streptozocin parenterally.

A further histological feature of specific interest was periportal inflammation as the presence of periportal inflammation is associated with more advanced disease in both adults and children. We identified a variety of models showing portal inflammation (Supporting Table S5), including chemically induced (e.g., monosodium glutamate), dietary (e.g., high fat, high fructose and high sucrose), and genetic (e.g., galectin-3 knockout) models. We noted that portal inflammation was the least frequently described histological feature (Supporting Fig. S3) and suspect that this may be influenced by underreporting.

**GENE EXPRESSION**

Out of 187 studies with animal model gene expression data, eight had performed a cross-species comparison (Supporting Table S6). Most studies found statistically significant overlap between human and murine expression, using a variety of different analysis methodologies. As mentioned, Giles et al. found that housing at thermoneutrality (compared to room temperature) increased the ability of gene expression profiles to predict the presence of NASH in humans from 82% to 89%. Two studies compared the expression of multiple different animal models. Firstly, Teufel et al. observed that the variation between species was substantially larger than within murine models and that only a few enriched pathways overlapped, with fructose-enriched HFD models showing...
### TABLE 3. Models with highest overall phenotype scores

| Model Name                           | Background | Sex | Age Started (Weeks) | Fat (%kcal) | Cholesterol (%Weight) | Fructose (%kcal) | Sucrose (%kcal) | Obesity | Insulin Resistance | Dyslipidemia | Metabolic Syndrome | Ballooning | NASH | Fibrosis | HCC | Max. Age | Max. Stage | Max. Age | Max. Stage | Max. Age | Max. Age | Max. Age |
|--------------------------------------|------------|-----|---------------------|-------------|-----------------------|------------------|-----------------|---------|-------------------|--------------|-------------------|------------|------|----------|-----|----------|-----------|----------|-----------|----------|----------|----------|----------|----------|
| HD example studies: PMID 29092796, 22834991, 23964070 | CS78U/6D | M   | 8                   | 57          |                       |                  |                 | Yes     | Yes               | Yes          | 3                 | 9         | 12    | Yes/No   | No  | 60       | 3         | 60       | 3         | 60       | 3         | 60       |
| HD example studies: PMID 23917411, 279997977, 27045862 | CS78U/6D | M   | 8                   | 60          |                       |                  |                 | Yes     | Yes               | Yes          | 3                 | 8         | 11    | Yes/No   | Yes | 29       | 16        | 1        | 33        | 34       | 1         | 34       |
| HD example studies: PMID 2339569, 2689237, 15741972 | Sprague-Dawley | M   | 5                   | 22          | 2                     |                  |                 | Yes     | Yes               | Yes          | 3                 | 9         | 12    | Yes/No   | Yes | 20       | 32        | 3        | 32        | 32       | 3         | 32       |
| HD example studies: PMID 26855552, 23200892 | Sprague-Dawley | M   | 8                   | 40          | 2                     |                  |                 | Yes     | Yes               | Yes          | 3                 | 9         | 12    | Yes/No   | Yes | 8        | 8         | 3        | 8         | 8        | 3         | 8        |
| HD example studies: PMID 23395669, 26889237, 15741972 | Sprague-Dawley | M   | 8                   | 22          | 2                     |                  |                 | Yes     | No                | No           | 2                 | 9         | 11    | Yes/No   | No  | 9        | 9         | 4        | 9         | 9        | 9         | 9        |
| HD example studies: PMID 29709927, 23964070 | Sprague-Dawley | M   | 9                   | 51          | 2.5                   |                  |                 | Yes     | No                | No           | 2                 | 10        | 12    | Yes/No   | Yes | 68       | 68        | 4        | 68        | 68       | Yes       | 68       |
| HD example studies: PMID 23197411, 23964070 | C57BL/6J  | M   | 8                   | 60          | 1.25                  |                  |                 | No      | Yes               | Yes          | 3                 | 9         | 12    | Yes/No   | Yes | 52       | 52        | 2        | 52        | 52       | Yes       | 52       |
| Western diet (high fat, high fructose) (example studies: PMID 28399832, 284859819) | C57BL/6J | M   | 8                   | 58          | 2.31                  |                  |                 | Yes     | Yes               | Yes          | 3                 | 9         | 12    | Yes/No   | Yes | 52       | 52        | 2        | 52        | 52       | Yes       | 52       |
| HD example studies: PMID 285999995 | C57BL/6J | M   | 8                   | 58          | 2.31                  |                  |                 | Yes     | Yes               | Yes          | 3                 | 8         | 11    | Yes/No   | Yes | 16       | 16        | 2        | 16       | 16        | Yes       | 16       |
| HD example studies: PMID 28399832, 284859819 | C57BL/6J | M   | 8                   | 58          | 2.31                  |                  |                 | Yes     | Yes               | Yes          | 3                 | 8         | 11    | Yes/No   | Yes | 50       | 50        | 3        | 50        | 50       | Yes       | 50       |
| High fat (trans-fat) + fructose (example studies: PMID 29221615, 2922421) | C57BL/6J | M   | 10                  | 42          | 0.1                   |                  |                 | Yes     | Yes               | Yes          | 3                 | 10        | 13    | Yes/No   | Yes | 8        | 24        | 3        | 52        | 52       | Yes       | 52       |
| Model Name | Background | Sex | Age (Weeks) | Fat (%kcal) | Cholesterol (%Weight) | Sucrose (%kcal) | Fructose (%Weight) | Chemical | Insulin Resistance | Dyslipidemia | Phenotype Score | Metabolic Syndrome | NASH | Fibrosis | HCC | Max. Stage | Max. Age | Max. Age | Max. Age | Max. Age |
|------------|------------|-----|-------------|-------------|----------------------|----------------|------------------|----------|-------------------|-------------|----------------|------------------|------|---------|-----|-----------|---------|---------|---------|---------|
| MCD (example studies: PMID 20520981) | Wistar | M | 7 | | | | | | | | | | | | | | |
| MCD + HFD (example studies: PMID 26828535, 23477499, 23028442) | C57Bl/6J | M | 8 | 60 | | | | | | | | | | | | | | |
| Choline-deficient diet (example studies: PMID 22613706, 15107972) | Wistar | M | 7 | | | | | | | | | | | | | | |
| Choline-deficient, L-amino-defined diet (example studies: PMID 17914985, 2348160, 27320964) | C57Bl/6J | M | 6 | | | | | | | | | | | | | | |
| Choline-deficient, L-amino-defined diet (example studies: PMID 24948200, 23996730, 30083132) | C57Bl/6J | M | 8 | | | | | | | | | | | | | | |
| HFD + STZ (example studies: PMID 28512251, 28110063, 23430339) | C57Bl/6J | M | 4 | 57 | 0.3 | 200µg | Yes | Yes | Yes | | | | | | | | |
| HFD + STZ (example studies: PMID 2834573, 2917945, 29216638) | C57Bl/6J | M | 4 | 60 | 0.3 | 200µg | No | Yes | Yes | | | | | | | | |
| ACOX1-Lampe1 (splice-site mutant) (example studies: PMID 29907396, 29563328) | C57Bl/6J | | | | | | | | | | | | | | | | |
| ACOX1-Lampe1 (splice-site mutant) + HFHCD (example studies: PMID 21760938, 29563328) | C57Bl/6J | | | | | | | | | | | | | | | | |
| ApoE*3Leiden + Western diet (example studies: PMID 29907396, 29563328) | C57Bl/6J | M | 9 | 33 | 1 | | | | | | | | | | | | | |
| Leptin deficiency (ob/ob) + high fat (trans-fat), fructose, cholesterol diet (example studies: PMID 29375205, 27326314, 29375204) | B6-V-Lepob/Jr | M | 5 | 40 | 2 | | | | | | | | | | | | | |
| Model Name | Background | Sex | Started (Weeks) | Fat (%kcal) | Cholesterol (%Weight) | Sucrose (%kcal) | Fructose (%Weight) | Age | Given Dose | Insulin Resistance | Metabolic Syndrome | Liver | Overall | Yes/No | Max. | Max. | Max. | Max. | Max. | Age | Yes/No | Age |
|------------|------------|-----|----------------|-------------|----------------------|---------------|------------------|-----|--------------|-------------------|-------------------|-------|---------|-------|------|------|------|------|------|------|-------|------|
| Leptin deficiency (ob/ob) + high fat (trans-fat), fructose, cholesterol diet (example studies: PMID 29107284, 29713129) | C57Bl/6J | M | 8 | 40 | 2 | 22 | Yes | Yes | Yes | 3 | 8 | 11 | Yes | 12 | Yes | 12 | 3 | 12 |
| MC4R-KO + Western diet (example studies: PMID 29022448, 29402900, 29402900) | C57Bl/6J | M | 8 | 41 | 0.21 | 34 | Yes | Yes | Yes | 3 | 9 | 12 | Yes | 52 | Yes | 52 | 3 | 52 | Yes | 52 |
| SHRSP5/Dmcr rats + HFD (example studies: PMID 27037902, 29899851) | SHRSP5/Dmcr | M | 6 | 47 | 5 | Yes | Yes | Yes | 3 | 9 | 12 | Yes | 16 | Yes | 16 | 4 | 16 |
| Zucker rats / fa/fa rats (example studies: PMID 19101115, 27636007, 16139386) | Zucker | M | | | | | Yes | Yes | Yes | 3 | 8 | 11 | Yes | 23 | Yes | 28 | 2 | 22 |

Rodent models with the highest overall phenotype scores (0-14), which had been used by at least two studies. The PubMed identification number of up to three studies using each model is given below the model name.

Abbreviations: ACOX1- Lampe1, acyl-CoA oxidase 1; HFHCD, high-fat high-cholesterol diet; MC4R-KO, melanocortin 4 receptor knockout; MCD, methionine-/choline-deficient diet; PMID, PubMed identification number; STZ, streptozocin.
the greatest similarity at the pathway level. Secondly, Tsuchida et al.\(^{(23)}\) included data from 22 different models (or time points) and found that male C57BL/6J mice fed a Western diet (high fat, high sucrose, high cholesterol) with high fructose or glucose content in water and i.p. \(\text{CCl}_4\) injection showed the greatest similarity to human NAFLD.

HETEROGENEITY IN NOMENCLATURE OF DIETARY MODELS

The use of specialist diets to induce hepatic steatosis, with or without obesity and insulin resistance, has been the mainstay of rodent models of NAFLD.\(^{(9)}\) Over 75% of all models in our database included some form of dietary perturbation. However, we observed that there was inconsistent use of terminology when comparing the names of diets and their composition.

For example, 16% (237/1,488) of models described as an HFD (without specifying additional components) also contained added cholesterol (Fig. 3). Overall, 22% (334/1488) of HFDs had some added cholesterol, choline, sucrose, or fructose/glucose.

Similar results were observed for 149 “Western diet” models, which most frequently involved 40%-45% kcal from fat, plus 30% kcal from sucrose and 0.2% cholesterol. However, there was substantial variability (Supporting Fig. S4), with many models described as “Western diet” including added fructose. In addition, 18 models were described as using “Western diets” but provided no detail on diet composition.

GENETIC ANIMAL MODELS OF NAFLD ACT THROUGH ADIPOSE DYSFUNCTION AND INNATE IMMUNITY

Understanding the genetics of NAFLD in humans has provided substantial insight into the pathogenesis of fatty liver disease. Concurrently, there have been hundreds of genetically modified animal models that display features of NAFLD to varying severity. We used our database to identify 433 human orthologues...
from genetically modified mice that display exacerbated severity of NAFLD. Using gene set enrichment analysis, we identified that these gene targets are most highly expressed in adipose tissue and liver (Supporting Fig. S5 and Table S7). Pathways relating to insulin resistance, adipogenesis, and innate immunity, as well as genes implicated in type 2 diabetes and related metabolic syndrome traits in humans, were enriched in our gene set (Supporting Fig. S5).

**RISK OF BIAS**

Recommendations for reporting of preclinical studies suggest the use of blinding, randomization, a prespecified protocol, and a sample size estimate. We assessed all 4,540 articles for these four risk of bias metrics and combined them into an overall score (0-4). Over half of all studies had a score of 0 or 1 (Supporting Fig. S6). Only 1.3% of all studies reported a power calculation, with blinding used in 19% and randomization in 37%.

**Discussion**

Preclinical animal studies of hepatic steatosis have been conducted for nearly 70 years with the aim of helping to elucidate the mechanisms of liver lipid metabolism and, more recently, to find effective treatments for NAFLD. This has resulted in an increasingly complex array of animal models. We performed a systematic analysis of animal models of NAFLD, providing a framework for their description, identifying the suitability of models for studying different aspects of the disease, and highlighting challenges of reproducibility.

We categorized over 3,900 unique models through detailed comparison of animal study design. This large number is due to variation in almost every aspect of design, including age of interventions, dietary composition, sex, and genetic background. Therefore, while many studies may initially appear to use the same model (e.g., high fat, high cholesterol in C57BL/6J mice), the majority have only been used by a single study. Consideration of precise details in study design is relevant in the light of recent data that suggest that even small differences in age or diet composition may affect treatment response in animal models of NAFLD.

Moreover, this has implications for understanding the “reproducibility crisis” of preclinical studies. Our results suggest that most models have never been replicated, which adds further variability in challenging in vivo studies with small effect sizes. We found that genetic models were the most frequently replicated and that, in their case, the perturbation was (usually) unambiguously defined (e.g., albumin-cyclization recombination liver-specific phosphatase and tensin homolog [PTEN] knockout compared to “Western diet”). However, genetically modified animals are often subject to compensatory germline expression changes affecting their metabolism through mechanisms that may often be difficult to identify.

We observed marked variability in the terminology of dietary interventions. “Atherogenic diet” and “Western diet” have been used in animal studies since the 1950s and 1980s, respectively, with their use increasing since preformulated diets became available from major laboratory feed suppliers. While there is some consensus on general composition between suppliers (e.g., atherogenic diets Harlan Teklad TD.88137 and Research Diets D12336), there does not appear to be a formal definition of terminology. From our observations, we suggest the development of consensus recommendations around the nomenclature of dietary compositions (e.g., Western diet >30% kcal from fat, >30% kcal from sucrose, no added fructose, <0.5% cholesterol) as this will support consistency and reproducibility. Similarly, an additional source of heterogeneity stems from the exact fat composition of different dietary interventions. Diets high in unsaturated fats (such as coconut oil–based diets) have been demonstrated to increase de novo lipogenesis more than diets high in saturated fats, including the widely used lard-based HFD, which may be an additional reason for phenotypic variation.

We have used this data set to explore whether there is a single “ideal” animal model that reflects the spectrum of human NAFLD or if different study designs should be used for specific animal phenotypes. To this end, we used a phenotype score in which we summarize the key measurable metabolic and histological features of NAFLD, which we identified following review of all included animal studies (Supporting Table S1). Although the principal aim of this score is to allow comparison across multiple papers, rather than giving an in-depth description of a single model, this phenotype score could be used as a baseline measure when developing and assessing preclinical models of NAFLD. While no model demonstrated all...
features of both histological NAFLD and the metabolic syndrome, several studies using a prolonged diet of high fat and high fructose had the highest overall scores for similarity to human NAFLD. The high-fat, high-fructose model was also identified to have the closest transcriptomic signature to human NAFLD. Therefore, this core model design appears to mimic the human phenotype most closely. Fibrosis and HCC development could be expedited in these models by additional treatment with intraperitoneal CCl4. If the focus of a preclinical study were to be advanced liver disease resulting from NAFLD, a high-fat, high-fructose model with injection of CCl4 might be preferable.

The link between a high-fat, high-fructose diet and NAFLD pathogenesis is in line with current evidence on human NAFLD. Diets high in fat might induce NAFLD through the high calorie burden and increased adiposity, leading to insulin resistance, as well as direct and differential effects of different fatty acids on lipogenesis, as discussed above. Proposed mechanisms describing the causative role of fructose in the development of NAFLD include direct up-regulation of de novo lipogenesis enzymes by fructose breakdown products in hepatocytes, production of acetyl CoA by conversion of fructose into acetate by the intestinal microbiota, and intestinal barrier deterioration leading to increased uptake of endotoxins from the gut to the liver, driving inflammation. Because few high-fat, high-fructose animal model designs have been precisely replicated, there are currently insufficient data to recommend specific dietary composition, genetic background, or timings of interventions.

The integral connection of adipose and liver metabolism is well established and supported by strong human genetic evidence, particularly from individuals with lipodystrophy. We have replicated this finding through analysis of rodent models with exacerbated NAFLD but interestingly also observed a role for pathways of innate inflammation (i.e., NF-κB, IL-6, TNF-α). In humans, steatohepatitis is a state of sterile inflammation, and all common human genetic variants so far reproducibly associated with NAFLD at genome-wide significance act through perturbation of lipid metabolism, including variants in or near PNPLA3, transmembrane 6 superfamily member 2, glucokinase regulator, hydroxysteroid 17β-dehydrogenase 13, membrane-bound O-acyltransferase domain containing 7, and mitochondrial amidoxime reducing component 1. There have been candidate studies suggesting that common variants in MER proto-oncogene tyrosine kinase and interferon-lambda are associated with severity of NAFLD in humans, though none of these variants have reached genome-wide significance, unlike for hepatitis C. In addition, one recent genome-wide association study (GWAS) using electronic medical records identified a GWAS-significant variant near IL17 receptor A associated with NAFLD activity score. The enrichment of inflammatory pathways in our analysis suggests that differential activity of the innate immune system might accelerate NASH across different rodent models. It will be interesting to see whether this is a finding specific to rodent models or whether further genetic evidence will implicate a causal role for innate immune activity in human NAFLD in the future.

We also examined gene expression in our data set, though only a small number of studies compared hepatic gene expression in animal models with human samples. Results were broadly congruous with our phenotype-based comparison, despite substantial heterogeneity in study design. It was not possible to perform a formal meta-analysis of these data due to lack of replication of each animal model and variation in age at sampling. In addition, selection of human samples for comparison would have been challenging given that some rodent models are focused on malignancy (with or without cirrhosis), while others principally cause steatosis without fibrosis. It should also be noted that several of these studies used the same human data set (GSE48452). Lastly, this cross-species methodology is principally limited by the substantially greater difference between human and all rodent samples than within rodent models.

The scoring system used in this study facilitated comparison across a large number of models, but small numerical differences (e.g., 12 vs. 13) may hide substantially different phenotypes (e.g., choline-deficient diet vs. high-fructose diet). When considering the utility of an individual model, the presence or absence of a specific feature (e.g., rapid development of HCC) would likely be more important than reported score in this study. In addition, due to institution-specific variables (e.g., animal housing conditions), investigators may observe phenotypic differences compared to previous reports. Therefore, when selecting a model design, we encourage investigators to interpret the phenotype score in combination with the number of independent
replications, as well as specific features (e.g., periportal inflammation). Where appropriate, replicating a previously described model will help the field move toward greater reproducibility in animal studies.

The vast majority of models used only male rodents; therefore, it was not possible to make a broad statement about whether models conducted in female versus male animals more closely resemble the human phenotype. Sex differences within models can be substantial, though are likely to still be smaller than between-species differences. Despite this, female animals are underrepresented in this field, particularly compared to the proportion of female participants in human NASH trials.

In this study, we have concentrated on disease phenotypes, which has facilitated the inclusion of a large number of studies and allowed focus on endpoints that are directly comparable to clinical practice. In some cases, we were limited by the level of detail reported by each individual study. For example, where two studies were otherwise identical, if one described use of “C57BL/6” mice and the other reported just “C57BL/6,” these would be identified as separate designs. Although this could have led us to overestimate the number of unique models, the importance of differences in genetic background in murine NAFLD phenotypes has been demonstrated by results from the Hybrid Mouse Diversity Panel. At the same time, we merged unique models with minimal differences in study design, such as percentage of fat in the diet varying by 1%, where the cutoffs were chosen manually based on modal values in our data, given our recent observation that most outcomes in rodent models of NAFLD can be modeled in continuous fashion. At present, the significance of, for instance, a 1%-2% difference in dietary fat is not known. Therefore, the precise number of “unique models” reported in this study is a function of this methodology. Lastly, there is a wide range of other variables that can affect the phenotype that we have not included in our analysis, including gut microbiome composition.

In summary, this systematic review has demonstrated substantial variability in the design of studies using rodent models of NAFLD. Due to variation in study design, most rodent models of NAFLD have only been used by a single study, highlighting the need for standardization and replication. This variation is compounded by a lack of consensus around nomenclature of diets. Genetic models that exacerbate NAFLD are enriched for genes involved in adipogenesis and innate immune pathways. Overall, high-fat, high-fructose diet models show the most phenotypic similarity to human NAFLD, though additional chemical liver injury or a prolonged study period might be required for the study of advanced stages of liver disease such as cirrhosis and HCC in these models.

Author Contributions: Y.R.I., H.H., D.d.G.H., and A.D.: Data curation, Formal analysis, Investigation, Writing - original draft, Writing - review and editing. Q.C., J.D., M.F., C.H., A.L., H.K.L., L.M., C.G.M., R.R., and M.U.: Data curation, Investigation, Writing - review and editing. I.A.R.: Investigation, Methodology, Writing - review and editing. J.P.M.: Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing.

REFERENCES
1) Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-2072.
2) Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.e10.
3) Paik JM, Golab P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007-2017. Hepatol Commun 2020;4:1769-1780.
4) Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol 2020;73:263-276.
5) Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
6) Luukkonen PK, Zhou Y, Sädevirta S, Leivonen M, Arola J, Orešič M, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 2016;64:1167-1175.
7) Mann JP, Pietzner M, Wittmans LB, Rolfe EDL, Kerrison ND, Imamura F, et al. Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. Hum Mol Genet 2020;29:3451-3463.
8) Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, et al. NAFLD: reporting histologic findings in clinical practice. Hepatology 2021;73:2028-2038.
9) Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44.
10) Feibraio MA, Reihe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metab 2019;29:18-26.
11) Hunter H, de Gracia Hahn D, Duret A, Im YR, Cheah Q, Dong J, et al. Weight loss, insulin resistance, and study design...
confound results in a meta-analysis of animal models of fatty liver. Elife 2020;9:e56753.

12) von Herrath M, Pagni PP, Grove K, Christoffersson G, Tang-Christensen M, Karlsen AE, et al. Case reports of pre-clinical replication studies in metabolism and diabetes. Cell Metab 2019;29:795-802.

13) Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—an web and mobile app for systematic reviews. Syst Rev 2016;5:210.

14) Eppig JT, Smith CL, Blake JA, Ringwald M, Kadin JA, Richardson JE, et al. Mouse Genome Informatics (MGI): resources for mining mouse genetic, genomic, and biological data in support of primary and translational research. In: Schughart K, Williams RW, eds. Systems Genetics: Methods and Protocols. New York, NY: Springer; 2017:47-73.

15) Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.

16) Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 2016;44(W90-W97.

17) R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.

18) Harrer M, Cuipiers P, Furukawa TA, Ebert DD. Doing Meta-Analysis in R: A Hands-on Guide. Erlangen, Germany: PROTECT Lab; 2019.

19) Cazanave SC, Podtelezhnikov A, Jensen K, Sennesah M, Vincent R, Banini BA, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 2016;65:579-588.

20) Cazanave S, Podtelezhnikov A, Jensen K, Sennesah M, Kumar DP, Min H-K, et al. The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci Rep 2017;7:17193.

21) Downman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 2014;184:1550-1561.

22) Tsuchida T, Lee YA, Fujinara N, Ybanez M, Allen B, Martins S, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018;69:385-395.

23) Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinopathologic correlation from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2009;49:809-820.

24) Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology 2016;151:513-525.e9.

25) Perdieu de Sert N, Hurst V, Ahammad B, Alam S, Avey MT, Baker SP, et al. The ARIFFV guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol 2020;18:e3000410.

26) Eilert ML, Dragstedt LR. Lipotropic action of lipocaic; a study of the effect of oral and parenteral lipocaic and oral inositol on the dietary fatty liver of the white rat. Am J Physiol 1946;147:346-351.

27) Nezvora VA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease—a practical approach for translational research. J Hepatol 2020;73:423-440.

28) Jaksiewicz K, Rossouw JE, Kritchevsky D, van Rensburg SJ, Fincham JE, Woodrow CW. The influence of diet and dimethyl-sulfoxhide on the small and large intestine of vervet monkeys. Br J Exp Pathol 1986;67:361-369.

29) Baker SP, Ogden E, Riddle JW. Serological detection of abnormal concentrations of serum lipoproteins in dogs on cholesterol-thiouracil atherogenic diets. Proc Soc Exp Biol Med 1953;82:119-122.

30) Duarte JAG, Carvalho F, Pearson M, Horton JD, Browning JD, Jones RG, et al. A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice. J Lipid Res 2014;55:2541-2553.

31) Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. J Hepatol 2018;69:272-274.

32) Friedman SL, Neuschwander-Tetri BA, Pinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908-922.

33) Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 2020;579:586-591.

34) Tang C, Wada S, Yang S, Gosis B, Zeng X, Zhang Z, et al. The small intestine shields the liver from fructose-induced steatosis. Nat Metab 2020;2:586-593.

35) Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab 2020;2:1034-1045.

36) Mann JP, Savage DB. What lipodystrophies teach us about the metabolic syndrome. J Clin Invest 2019;130:4009-4021.

37) Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Lauren J, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.

38) Parisinos CA, Wilmar HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241-251.

39) Emdin CA, Haas ME, Khara AW, Aragam K, Chaffin M, Klarin D, et al. A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease. PLoS Genet 2016;12:e100629.

40) Cai B, Dongiovanni P, Corey KE, Wang X, Shmarakov IO, Zheng ZE, et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab 2020;31:406-421.e7.

41) Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015;6:6422.

42) Patin E, Kutalik Z, Guergnon J, Bibert S, Naipals B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012;143:1244-1252.e12.

43) Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019;17:135.

44) Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Schughart K, Williams RW, eds. Systems Genetics: Methods and Protocols. New York, NY: Springer; 2017:47-73.

45) Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab 2020;2:1034-1045.

46) Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Lauren J, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
panel highlights mitochondrial dysfunction in non-alcoholic fatty liver disease. Cell Systems 2018;6:103-115.e7.

47) Norheim F, Bjellaas T, Hui ST, Chella Krishnan K, Lee J, Gupta S, et al. Genetic, dietary, and sex-specific regulation of hepatic ceramides and the relationship between hepatic ceramides and IR. J Lipid Res 2018;59:1164-1174.

48) Hui ST, Parks BW, Org E, Norheim F, Che N, Pan C, et al. The genetic architecture of NAFLD among inbred strains of mice. Elife 2015;4:e05607.

49) Hui ST, Kurt Z, Tuominen I, Norheim F, Davis RC, Pan C, et al. The genetic architecture of diet-induced hepatic fibrosis in mice. HEPATOLOGY 2018;68:2182-2196.

50) Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020;11:4982.

Author names in bold designate shared co-first authorship.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31897/suppinfo.